Bayer to Market Biocon Insulin in China
Indian biotech major Biocon
Ltd has roped in Bayer HealthCare to market its recombinant human insulin Insugen in the Chinese market, the company //said in a statement Wednesday.
The Bangalore-based biotech firm plans to launch Insugen in China by 2007-08 after completing the registration tria...
Kalam Dedicates New Cancer Drug Developed By Biocon
President A P J Abdul Kalam today dedicated to the nation India's first indigenously developed drug for treating head and neck cancer. //
Kalam congratulated Biocon
scientists for developing the monoclonal antibody, BioMab EGFR (epidermal growth factor receptor), which company officials said...
Contract Drug Development Resource, goBalto, Launches New Web-Based Platform, goBalto.com
... and manufacturing capabilities to biotech and pharmaceutical companies around the globe," said Kiran-Mazumdar Shaw, Chairman and Managing Director of biocon
Limited. "The goBalto partnering website provides us with a highly cost-effective channel to reach our target customers compared to traditional option...
Biocon Net Profit Up by 15 Percent for Fiscal Year
... Indian biotechnology major biocon
Ltd. Thursday announced a 15 percent surge in its ...ran Mazumdar-Shaw, chairman and managing director, biocon
and its subsidiaries have created a unique matrix ...
Biocon Unveils Renal Therapies for Kidney Disorders
... India's premier biotechnology firm biocon
Ltd Thursday announced the launch of renal therapy products for treating ki...gressive competition from Indian and multinational players in the country," biocon
marketing president Rakesh Bamzai said.
According to "Kidney Internat...
Biocon to Launch Anti-arthritis Drug
... New Delhi: India's leading biotech firm biocon
Monday said it would launch in the next three-four years a new anti-arthrit...tunity for us," said Kiran Mazumdar Shaw, chairman and managing director of biocon
Ltd, on the sidelines of the 22nd Indian Economic Summit here.
Biocon To Shift Focus On Innovation To Accelerate Growth
Ltd, India's largest biotechnology firm, has made ...iver strong and sustainable growth in the future," biocon
chairperson Kiran Mazumdar-Shaw told reporters her...tments and regulatory time lines.
According to biocon
chief operating officer (COO) Arun Chandavarkar, t...
Biocon To Raise Its Investment In Scotland
... an Indian biotechnology company will raise its investments in Scotland which is seen to be an emerging destination for clinical development of drugs. biocon
is reported to already have // a close relationship with life sciences organizations in Scotland. There are more than 550 life sciences organization...
India set to become the global knowledge hub
...f its innovative skill base. This is where the Silicon Valley scored," says biocon
founder Kiran Mazumdar-Shaw.
"But it is heartening that Bangalore and H...haw, who became the richest Indian woman with a wealth of $400 million when biocon
was listed in 2004.
India today has more than 250 universities and many...
Biocon to colloborate for development of Oral peptide drugs for heart diseases.
... The Indian Biotech Company, biocon
to colloborate with Nobex Corporation of United St...g for cardiovascular diseases. The spokesperson of biocon
informed that the company has gone into global res...uct for treatment of cardiovasculoar diseases. The biocon
press release said, “The collaboration combines th...
Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market
PITTSBURGH, June 29 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL ) today announced that it has executed a definitive agreement with Biocon
Limited, a publicly traded company on the Indian stock exchanges, for an exclusive collaboration on the development, manufacturing, supply and commercia...
Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009
...as well. In addition, we took an important initial step in one of our targeted areas of future growth by entering into a collaborative agreement with biocon
in the area of generic biologics."
Coury continued: "On the strength of the momentum provided by our first half results, coupled with what we ...
NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
...d and Neck Cancer; Type: General Poster Session; Time: Monday June 1, 8:00 AM to 12:00 PM; Location: Level 2, West Hall C). The trial was sponsored by biocon
Ltd., the licensee from CIMAB S.A. for nimotuzumab in India.
About YM BioSciences
YM BioSciences Inc. is a life sciences product development...
YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING
... presentation will report results from a randomized trial of nimotuzumab (aka BIOMAb/TheraCIM/h-R3) in patients with head and neck cancer conducted by biocon
Limited (Bangalore, India), a licensee of CIMAB SA, YM's licensor, at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) held...